AUTL · Autolus Therapeutics plc
$2.15
-0.07 (-3.15%)
At close · Aug 14
Market Cap
$572.25M
Shares
266.16M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Ryan Richardson | Class I director | Appointed | 2025-12-02 |
| Patrick McIlvenny | Principal Accounting Officer | Appointed | 2025-11-12 |
| Rob Dolski | principal accounting officer | Appointed | 2025-04-03 |
| Michael W. Bonney | Chair of the Board | Appointed | 2024-04-01 |
| Michael W. Bonney | Class II director | Appointed | 2024-04-01 |
| Ravi M. Rao | Class I director and member of the Research and Development Committee | Appointed | 2024-04-01 |
| John Johnson | Director | Resigned | 2024-04-01 |
| Robert (“Bob”) W. Azelby | Class II director | Appointed | 2024-01-10 |
| Elisabeth ("Lis") Leiderman, M.D. | Class II director | Appointed | 2023-12-22 |
| Kapil Dhingra, M.D. | Director | Resigned | 2023-12-22 |
Key facts
CIK
1730463
CUSIP
05280R100
13F (30d)
81 filings
79 filers
Visit website
Investor relations